Search research articles
Contact Us
Filters
Showing results (21-30 of 56) with videos related to
Page
of 6
Sort By:
Brachytherapy
|
May 26, 2019
Changes in ADC and T2-weighted MRI-derived radiomic features in patients treated with focal salvage HDR prostate brachytherapy for local recurrence after previous external-beam radiotherapy
Sangjune Laurence Lee, Ananth Ravi, Gerard Morton, et al.
Future Oncology (London, England)
|
December 5, 2014
Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma
Jonathan Klein, Renee Korol, Simon S Lo, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 13, 2021
Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters
Hendrick Tan, Patrick Cheung, Alexander V Louie, et al.
Brachytherapy
|
December 15, 2017
Dosimetric impact of inter-observer catheter reconstruction variability in ultrasound-based high-dose-rate prostate brachytherapy
Alexandru Nicolae, Jure Murgic, Ivan Kruljac, et al.
Practical Radiation Oncology
|
June 19, 2022
A Prospective Study of Magnetic Resonance Imaging-guided Focal Salvage High-dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients
Mark T Corkum, Gerard Morton, D Andrew Loblaw, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 20, 2011
Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
Gerard Morton, Andrew Loblaw, Patrick Cheung, et al.
Cancers
|
August 29, 2024
Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model
Hanzhi Wang, Linsey Gong, Xiaoyong Huang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 28, 2020
Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial
Mark Corkum, Andrew Loblaw, Yaser Hasan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 9, 2020
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy
Gerard Morton, Merrylee McGuffin, Hans T Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 9, 2016
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy
Gerard Morton, Hans T Chung, Merrylee McGuffin, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 56) with videos related to
Sort By:
Page
of 6
Brachytherapy
|
May 26, 2019
Changes in ADC and T2-weighted MRI-derived radiomic features in patients treated with focal salvage HDR prostate brachytherapy for local recurrence after previous external-beam radiotherapy
Sangjune Laurence Lee, Ananth Ravi, Gerard Morton, et al.
Future Oncology (London, England)
|
December 5, 2014
Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma
Jonathan Klein, Renee Korol, Simon S Lo, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 13, 2021
Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters
Hendrick Tan, Patrick Cheung, Alexander V Louie, et al.
Brachytherapy
|
December 15, 2017
Dosimetric impact of inter-observer catheter reconstruction variability in ultrasound-based high-dose-rate prostate brachytherapy
Alexandru Nicolae, Jure Murgic, Ivan Kruljac, et al.
Practical Radiation Oncology
|
June 19, 2022
A Prospective Study of Magnetic Resonance Imaging-guided Focal Salvage High-dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients
Mark T Corkum, Gerard Morton, D Andrew Loblaw, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 20, 2011
Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
Gerard Morton, Andrew Loblaw, Patrick Cheung, et al.
Cancers
|
August 29, 2024
Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model
Hanzhi Wang, Linsey Gong, Xiaoyong Huang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 28, 2020
Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial
Mark Corkum, Andrew Loblaw, Yaser Hasan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 9, 2020
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy
Gerard Morton, Merrylee McGuffin, Hans T Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 9, 2016
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy
Gerard Morton, Hans T Chung, Merrylee McGuffin, et al.
Page
of 6